As the trusted authority on the risks and benefits of the products in our portfolio, we empower healthcare decisions regarding their safe and appropriate use.
▼ This medicinal product is subject to additional monitoring, which will allow the rapid identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.
Comirnaty dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The use of this vaccine should be in accordance with official recommendations.
The Summary of Product Characteristics (SmPC) for Comirnaty is available here.
*Contact Medical Information. 09h - 18h Monday to Friday.
Submit a medical question for Pfizer prescription products.
To report an adverse event related to a Pfizer product, click on the link:
www.pfizersafetyreporting.com
If you cannot use the above website, please contact Pfizer pharmacovigilance at
FRA.AEReporting@pfizer.com.
You may also report adverse events online on the Ministry of Health’s website ‘Portail de signalement des événements sanitaires indésirables’ at https://signalement.social-sante.gouv.fr